The Indian pharmaceutical industry is a success story providing employment for millions and ensuring that essential drugs

at affordable prices are available to the vast population of this subcontinent. Richard Gerster The Indian Pharmaceutical Industry today is in the front rank of Indias science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously. Playing a key role in promoting and sustaining development in the vital field of medicines, Indian Pharma Industry boasts of quality producers and many units approved by regulatory authorities in USA and UK. International companies associated with this sector have stimulated, assisted and spearheaded this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world.

Growth Scenario in 2010

India's pharmaceutical industry is now the third largest in the world in terms of volume. Its rank is 14th in terms of value. Between September 2008 and September 2009, the total turnover of India's pharmaceuticals industry was US$ 21.04 billion. The domestic market was worth US$ 12.26 billion. This was reported by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. As per a report by IMS Health India, the Indian pharmaceutical market reached US$ 10.04 billion in size in July 2010. A highly organized sector, the Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. Know more out this in our article on Indian Pharmaceutical Industry- Future Trends Also check out Pharmaceutical Market Trends 2010

Leading Pharmaceutical Companies

In the domestic market, Cipla retained its leadership position with 5.27 per cent share. Ranbaxy followed next. The highest growth was for Mankind Pharma (37.2%). Other leading companies in the Indian pharma market in 2010 are:

Sun Pharma (25.7%) Abbott (25%) Zydus Cadila (24.1%) Alkem Laboratories (23.3%) Pfizer (23.6 %) GSK India (19%) Piramal Healthcare (18.6 %) Lupin (18.8 %)

For details check out List of Top 10 Pharmaceutical Companies in India

Future Prospects
The Indian pharmaceuticals market is expected to reach US$ 55 billion in 2020 from US$ 12.6 billion in 2009. This was stated in a report title "India Pharma 2020: Propelling access and acceptance, realising true potential" by McKinsey & Company. In the same report, it was also mentioned that in an aggressive growth scenario, the pharma market has the further potential to reach US$ 70 billion by 2020 Due to increase in the population of high income group, there is every likelihood that they will open a potential US$ 8 billion market for multinational companies selling costly drugs by 2015. This was estimated in a report by Ernst & Young. The domestic pharma market is estimated to touch US$ 20 billion by 2015. The healthcare market in India to reach US$ 31.59 billion by 2020. The sale of all types of pharmaceutical drugs and medicines in the country stands at US$ 9.61 billion, which is expected to reach around US$ 19.22 billion by 2012. Thus India would really become a lucrative destination for clinical trials for global giants. There was another report by RNCOS titled "Booming Pharma Sector in India" in which it was projectedt that the pharmaceutical formulations industry is expected to prosper in the same manner as the pharmaceutical industry. The domestic formulations market will grow at an annual rate of around 17% in 2010-11, owing to increasing middle class population and rapid urbanisation. Read More in Future Prospects of Indian Pharma Industry.

Characteristics of Indian Pharmaceutical Industry

The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. It has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control 70% of the market with market leader holding nearly 7% of the market share. It is an extremely fragmented market with severe price competition and government price control. The pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectibles. There are about 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units). These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical formulations. Following the de-licensing of the pharmaceutical industry, industrial licensing for most of the drugs and pharmaceutical products has been done away with. Manufacturers are free to produce any drug duly approved by the Drug Control Authority. Technologically strong and totally selfreliant, the pharmaceutical industry in India has low costs of production, low R&D costs, innovative scientific manpower, strength of national laboratories and an increasing balance of trade. The Pharmaceutical Industry, with its rich scientific talents and research capabilities, supported by Intellectual Property Protection regime is well set to take on the international market.

Why India?
Competent workforce: India has a pool of personnel with high managerial and technical competence as also skilled workforce. It has an educated work force and English is commonly used. Professional services are easily available. Cost-effective chemical synthesis: Its track record of development, particularly in the area of improved cost-beneficial chemical synthesis for various drug molecules is excellent. It provides a wide variety of bulk drugs and exports sophisticated bulk drugs. Legal & Financial Framework: India has a 53 year old democracyand hence has a solid legal framework and strong financial markets. There is already an established international industry and business community. Information & Technology: It has a good network of world-class educational institutions and established strengths in Information Technology. Globalisation: The country is committed to a free market economy and globalization. Above all, it has a 70 million middle class market, which is continuously growing. Consolidation: For the first time in many years, the international pharmaceutical industry is finding great opportunities in India. The process of consolidation, which has become a generalized phenomenon in the world pharmaceutical industry, has started taking place in India.

Steps to strengthen the Industry

Indian companies need to attain the right product-mix for sustained future growth. Core competencies will play an important role in determining the future of many Indian pharmaceutical companies in the post product-patent regime after 2005. Indian companies, in an effort to consolidate their position, will have to increasingly look at merger and acquisition options of either companies or products. This would help them to offset loss of new product options, improve their R&D efforts and improve distribution to penetrate markets. Research and development has always taken the back seat amongst Indian pharmaceutical companies. In order to stay competitive in the future, Indian companies will have to refocus and invest heavily in R&D. The Indian pharmaceutical industry also needs to take advantage of the recent advances in biotechnology and information technology. The future of the industry will be determined by how well it markets its products to several regions and distributes risks, its forward and backward integration capabilities, its R&D, its consolidation through mergers and acquisitions, comarketing and licensing agreements.

The Indian pharmaceutical industry is highly regulated. The Government controls prices of a large number of bulk drugs and formulations. Profit margins of players vary widely in both domestic and export sales due to many factors.

Domestic Trade of India Pharma Industry

More than 85% of the formulations produced in the country are sold in the domestic market. India is largely self-sufficient in case of formulations. Some life saving, new generation underpatent formulations continue to be imported, especially by MNCs, which then market them in India. Overall, the size of the domestic formulations market is around Rs160bn and it is growing at 10% p.a.

Exports of Indian Pharmaceuticals

Over 60% of Indias bulk drug production is exported. The balance is sold locally to other formulators. Indias pharmaceutical exports are to the tune of Rs87bn, of which formulations contribute nearly 55% and the rest 45% comes from bulk drugs. In financial year 200, exports grew by 21%. Indias pharmaceuticals imports were to the tune of Rs20.3bn in FY2001. Imports have registered a CAGR of only 2% in the past 5 years. Import of bulk drugs have slowed down in the recent years. The exports of Pharmaceuticals during the year 1998-97 were Rs 49780 million. From a meager Rs 46 crores worth of Pharmaceuticals, Drugs and Fine Chemicals exports in 1980-81, pharmaceutical exports has risen to approximately Rs 6152 Crores (Prov.1998-99), a rise of 11.91% against the last year exports. Amongst the total exports of India, the percentage share of Drugs, Pharmaceuticals and Fine Chemicals during April-October (2000-2001) was 4.1%, an increase of 7%.
Research & Development is the key to the future of pharmaceutical industry. The pharmaceutical advances for considerable improvement in life expectancy and health all over the world are the result of a steadily increasing investment in research. There is considerable scope for collaborative R & D in India. India can offer several strengths to the international R & D community. These strengths relate to availability of excellent scientific talents who can develop combinatorial chemistry, new synthetic molecules and plant derived candidate drugs. R & D in the pharmaceutical industry in India is critical to find answers for some of the diseases peculiar to a tropical country like India and also for finding solutions for unmet medical needs. Industrial R & D groups can carry out limited primary screening to identify lead molecules or even candidate drugs for further in vivo screening, pre-clinical pharmacology, toxicology, animal and human pharmacokinetics and metabolic studies before taking them up for human trials. In such collaborations, harmonized standards of screening can be assured following established good laboratory practices. The R & D expenditure by the Indian pharmaceutical industry is around 1.9% of the industrys turnover.

This obviously, is very low when compared to the investment on R & D by foreign research-based pharma companies. They spend 10 - 16% of the turnover on R & D. However, now that India is entering into the Patent protection area, many companies are spending relatively more on R & D. When it comes to clinical evaluation at the time of multi-center trials, India would provide a strong base considering the real availability of clinical materials in diverse therapeutic areas. Such active collaboration will be mutually beneficial to both partners. According to a survey by the Pharmaceutical Outsourcing Management Association and Bio/Pharmaceutical Outsourcing Report, pharmaceutical companies are utilizing substantially the services of Contract Research Organizations (CROs). Indian Pharmaceutical Industry, with its rich scientific talents, provides cost-effective clinical trial research. It has an excellent record of development of improved, cost-beneficial chemical syntheses for various drug molecules. Some MNCs are already sourcing these services from their Indian affiliates. The Pharmaceutical and Biotechnology Industry is eligible for weight deduction for R&D expense upto 150%. These R&D companies will also enjoy tax holiday for 10 years. A promotional research and development fund of Rs.150 crores is set up by the Government to promote research and development in the pharmaceuticals sector. he Pharmaceutical industry in India is the world's third-largest in terms of volume and stands 14th in terms of value.[1] According to Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, the total turnover of India's pharmaceuticals industry between 2008 and September 2009 was US$21.04 billion.[2] While the domestic market was worth US$12.26 billion. Sale of all types of medicines in the country is expected to reach around US$19.22 billion by 2012. Exports of pharmaceuticals products from India increased from US$6.23 billion in 2006-07 to US$8.7 billion in 2008-09 a combined annual growth rate of 21.25%.[2] According to PricewaterhouseCoopers (PWC) in 2010, India joined among the league of top 10 global pharmaceuticals markets in terms of sales by 2020 with value reaching US$50 billion.[3]

Products Gufic Biosciences has been known for its products in the area of Pharma, Herbal/Ayurvedic, Consumer Products and Personal Hygiene Products. Pharma Products : Ridol Tablets, Vipro-Fe Syrup, Zad-G and Eben Tablets & Suspension. Products successfully developed and marketed in the recent years are Optifer Capsules, Flabone Chewable Tablets, Aquadil-P Syrup, Nucart-OA Tablets, Rabol Tablets, Rabol-D Capsules, Menogia Tablets and Injection, Menogia-MF Tablets, Tocolyte Tablets and Injection, Tocolyte-SR Tablets, Prodox Tablets/Dispersible Tablets and Dry Syrup. Herbal/Ayurvedic Products : Sallaki Tablets, Sallaki Ointment, Imunocin Tablets and Syrup, Eugynin-L Tablets, Aswal Plus Tablets, Kofend Syrup. Consumer Products : Stretch Nil Lotion, Roll-On Cold Rub Oil, Care Ointment and Cream. Personal Hygiene Products : Shapers and Actislim Sanitary Napkins

The Centre comprises of four main functional areas viz., Formulation Development, Analytical Development, Packaging Development and Documentation. A unique integrated approach has been adopted; wherein Formulation Development work is actively supported by Analytical Development and Packaging Development functions, eventually leading to Documentation. Gufic R&D Centre occupies an area of about 6000 sq.ft. and is equipped with sophisticated lab/pilot scale machines to simulate production conditions for development of all dosage forms e.g. Tablets, Capsules, Dry Syrups, Dispersible Tablets, Vaginal Tablets, Ointments, Creams, Gels, Liquid Syrups, Suspensions, Emulsions, Lotions, Solid and Liquid Injectables, etc. The Formulation Development labs have been designed to include both Lab scale development work as well as Pilot scale development work facilities. The lab scale facilities is equipped for development of all types of conventional pharmaceutical dosage forms. While the pilot scale up labs have been equipped to simulate conditions similar to that of production by use of pilot scale prototype equipments and machines such as Mass mixer, Double cone blender, Sifter, Multimill, Planetary mixer, Fluid Bed Drier, Tray Drier, 16 Station Rotary Tablet compression machine, Colloid Mill, Coating Pan, Capsule filling machine, Ointment/Cream filling and crimping machine, Ampoule/Vial filling and sealing machine, ROPP Cap Sealing Machine, Filtration Units for Oral Liquids and for Sterile Preparations, Laminar Flow Bench, Blister and Foil Packing machine. The products under development are subjected to accelerated stability study conditions using Incubators/Ovens set at various temperature and humidity, as per ICH guidelines. The Analytical Development labs support Formulation Development activity by developing New methods for New molecules and New formulations, New stability indicating Test procedures and carrying out analysis of accelerated stability studies samples. The analytical development lab has Modern Instruments such as Binary Gradient High Pressure Liquid Chromatograph, UV-Visible Spectrophotometer, Gas Chromatograph, Potentiometric Autotitrator, Polarimeter, Refractometer, Brookfield Viscometer, 6-Station Dissolution Rate Apparatus, etc. The in-house Microbiological Testing for Antibiotic Assay, Sterility, Microbial Count, etc., is carried out with the help of equipments such as B.O.D. Incubator, Antibiotic Assay Zone Reader, Laminar Flow Bench, Autoclave etc. The Packaging Development Lab is equipped with equipments such as Vibration Tester, Drop Tester, Tensile Strength Tester, Substance Indicator for GSM measurements, Cobb Tester and Bursting Strength Tester to develop and evaluate the packaging from immediate container/closure stage to the final shipper pack stage. The Centre subscribes to Indian and International Scientific Journals for in-house reference work. The Centre is manned by qualified and experienced Scientists from the field of Pharmaceutical Sciences, Analytical Chemistry, Microbiology, and Packaging Technology.

R &D functions

New Pharma Products Formulation Development Innovative Dosage Form Development New Drug Delivery Systems viz., Sustained Release Products

Newer Platform Technology Development viz., Colon Targeted Products Analytical Method Development and Standardisation of Analytical Test Procedures Packaging Development Product Development for Exports Novel Herbal based Product Development

Therapeutic segments

Anti-infectives Orthopaedic Disorders Gynaecological Disorders Gastrointestinal Disorders

http://www.guficbio.com/rd/funcations.htm http://www.guficbio.com/rd/therapeutic.htm http://www.guficbio.com/rd/products.htm seeds

With the expertise created in the field of agriculture, over the years, along with the right type of research, Gufic has entered into hybrid vegetable seeds. Gufic seeds deals in all major vegetable seeds namely, tomato, chilli, cabbage, cauliflower, capsicum, coriander, bhendi, bottle gourd, bitter gourd, ridge gourd, brinjal, cucumber and watermelon. It is bringing out varieties/hybrids as per the local demands and preferences for particular characteristics in a crop. Towards this goal, Gufic seeds has already made arrangements with world class breeders and companies to get excellent seed material for development and promotions. Company commands the association of skilled, accomplished and seasoned professionals in research, production and marketing and we shall be striving to bring to you the best of hybrids and varieties to suit specific requirements on continues basis.

Manufacturing
Presentation Vial Vial Vial Vial / Tablet Vial / Tablet

Vial Vial Vial / Tablet Vial / Tablet Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial / Tablet Vial Vial Vial Vial Vial Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet

Capsules Injection Tablet Tablet Tablet Tablet Tablet Injection

Molecule Vial Vial Vial Vial / Tablet Vial / Tablet Vial Vial Vial / Tablet Vial / Tablet Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial Vial / Tablet

Presentation

Vial Vial Vial Vial Vial Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Capsules Injection Tablet Tablet Tablet Tablet Tablet Injection

Molecule Follicle Stimulating Hormone Menotropin Human Chorionic Gonadotrophin Rabeprazole Sodium Omeprazole Sodium Pantoprazole Sodium Esomeprazole Sodium

Isoxsuprine Hydrochloride Tranexamic acid Piperacillin + Tazobactam Sodium Ceftriaxone Sodium Azithromycin Amphotericin-B Dobutamine Hydrochloride Sodium Niroprusside Cefpirome Sulphate Sulbactum + Cefoperazone Sodium Meropenen Trihydrate Teicoplanin Vancomycin Hydrochloride Ketoprofen Acyclovir sodium Haemocoagulase Zoledronic acid Urokinase Streptokinase Ibandronate Monosodium Monohydrate Hydrocortisone Sodium Succinate Parecoxib Sodium Hyaluronate Filgrastim (rhG-CSF) Imipenam Silastatin Gatifloxacin Candesartan Indapamide SR Trimetazidine MR Felodipine ER Perindopril Clopidogrel Simvastatin MR Rozuvastatin Gliclazide MR Metformin MR Glimepiride Pioglitazone Sodium Valproate NA Valproate + Valporic Acid Carbamazepine CR Respiridon Sertraline Ziprasidone Ziprasidone

Itopride HCl Tegaserod Meleate Balsalazide Sodium Cefprodoxime Proxetil Levofloxacin Paracetomol Strength 75 / 150 I.U. 75 / 150 I.U. 5000 20 ng 40 mg 40 mg 40 mg 5 mg 4.5 gm 125 / 600 mg 100 / 500 mg 50 mg 250 mg 50 mg 1 gm 1 gm 500 mg / 1 gm 400 mg 500 mg 100 mg 250 mg 1 ml 2,50,000 7,50,000 / 15,00,000 2 ml 40 mg 1 ml 500 mg 500 mg 200 / 300 / 400 mg 8 / 16 mg 1.5 mg 35 mg 2.5 / 5 / 10 mg

2 / 4 mg 75 mg 60 mg 5 / 10 / 20 mg 30 / 60 mg 850 mg 1 / 2 / 3 mg 15 / 30 mg

20 / 40 / 60 mg 20 mg 50 mg 6 mg 750 mg 100 / 200 mg 500 mg

Follicle Stimulating Hormone Menotropin Human Chorionic Gonadotrophin Rabeprazole Sodium Omeprazole Sodium Pantoprazole Sodium Esomeprazole Sodium Isoxsuprine Hydrochloride Tranexamic acid Piperacillin + Tazobactam Sodium Ceftriaxone Sodium Azithromycin Amphotericin-B Dobutamine Hydrochloride Sodium Niroprusside Cefpirome Sulphate Sulbactum + Cefoperazone Sodium Meropenen Trihydrate Teicoplanin Vancomycin Hydrochloride Ketoprofen Acyclovir sodium Haemocoagulase Zoledronic acid

Urokinase Streptokinase Ibandronate Monosodium Monohydrate Hydrocortisone Sodium Succinate Parecoxib Sodium Hyaluronate Filgrastim (rhG-CSF) Imipenam Silastatin Gatifloxacin Candesartan Indapamide SR Trimetazidine MR Felodipine ER Perindopril Clopidogrel Simvastatin MR Rozuvastatin Gliclazide MR Metformin MR Glimepiride Pioglitazone Sodium Valproate NA Valproate + Valporic Acid Carbamazepine CR Respiridon Sertraline Ziprasidone Ziprasidone Itopride HCl Tegaserod Meleate Balsalazide Sodium Cefprodoxime Proxetil Levofloxacin Paracetomol Strength 75 / 150 I.U. 75 / 150 I.U. 5000 20 ng 40 mg 40 mg 40 mg 5 mg

4.5 gm 125 / 600 mg 100 / 500 mg 50 mg 250 mg 50 mg 1 gm 1 gm 500 mg / 1 gm 400 mg 500 mg 100 mg 250 mg 1 ml 2,50,000 7,50,000 / 15,00,000 2 ml 40 mg 1 ml 500 mg 500 mg 200 / 300 / 400 mg 8 / 16 mg 1.5 mg 35 mg 2.5 / 5 / 10 mg 2 / 4 mg 75 mg 60 mg 5 / 10 / 20 mg 30 / 60 mg 850 mg 1 / 2 / 3 mg 15 / 30 mg

20 / 40 / 60 mg 20 mg 50 mg 6 mg

750 mg 100 / 200 mg 500 mg

Gufic Bioscience Ltd. Address N.H. NO. 8, NEAR GRID, KABILPORE, Navsari - 396424, Gujarat, India Phone No 91-2637-258077/258078 Contact Person MR. VIMAL KUMAR SOLANKI Mobile +91942692420

ompany Name Gufic Biosciences Limited Contact Person Dr.M.G.Dhapalapur Address Old Sankar Jyot School Building, 2nd,3rd,4th Floor, Above Bank Of Maharasthra, Next to Shopper's Stop, Andheri(W) Mumbai, Maharashtra, India. Zip / Postal Code 400 058 Telephone +91 - 22 - 67261009 ,09324209193 Fax Email Click here to email us Website www.guficbio.com Company Info Factory: Kabilpure Navsari Gujarat - 396 424 PH: 91-2637-58077, 58078 FAX; 91-2637-58280 E-MAIL: ghclnvs@bom5.vsnl.net.in Contact: Dr.M.G.Dhapalapur(Vice-President)

Products Gufic Biosciences has been known for its products in the area of Pharma, Herbal/Ayurvedic, Consumer Products and Personal Hygiene Products. Pharma Products : Ridol Tablets, Vipro-Fe Syrup, Zad-G and Eben Tablets & Suspension. Products successfully developed and marketed in the recent years are Optifer Capsules, Flabone Chewable Tablets, Aquadil-P Syrup, Nucart-OA Tablets, Rabol Tablets, Rabol-D Capsules, Menogia Tablets and Injection, Menogia-MF Tablets, Tocolyte Tablets and Injection, Tocolyte-SR Tablets, Prodox Tablets/Dispersible Tablets and Dry Syrup. Herbal/Ayurvedic Products : Sallaki Tablets, Sallaki Ointment, Imunocin Tablets and Syrup, Eugynin-L Tablets, Aswal Plus Tablets, Kofend Syrup. Consumer Products : Stretch Nil Lotion, Roll-On Cold Rub Oil, Care Ointment and Cream. Personal Hygiene Products : Shapers and Actislim Sanitary Napkins

The Gufic R&D Centre - Technology Development Dept., is a state-of-the-art research laboratory. The centre commenced functioning in July 1995 and has been designed with a view to be fully dedicated towards a newer concept of 'Total Product Development'. It was created to meet the challenges of the emerging global market, as well as the domestic market requirement, by developing New Pharmaceutical Products, New Drug Delivery Systems (NDDS), New Platform Technologies which will enhance the quality of life, globally.

R& D functions

New Pharma Products Formulation Development Innovative Dosage Form Development New Drug Delivery Systems viz., Sustained Release Products Newer Platform Technology Development viz., Colon Targeted Products Analytical Method Development and Standardisation of Analytical Test Procedures Packaging Development Product Development for Exports Novel Herbal based Product Development

Gufic Biosciences is a Private Sector Organisation that offers services in Pharmaceuticals/ BioTech/ Research with An nual Total Turnover of 10-100 Crs and with Employee Strength of 501-1000.

http://info.shine.com/company/Gufic-Biosciences-Ltd/4148.aspx

health
Healthcare and personal hygiene are evolving like never before. It's to match steps with changing lifestyles; eating habits; work culture; environmental changes and associated ailments or needs. The most reassuring fact about today's life is that, though after a fifty-year-long slumber, people are going back to nature. Natural foods, natural cosmetics, natural therapies, etc. Gufic believes, it's a welcome change. Gufic, with one of the finest Tissue Culture labs in India, along with a sophisticated R&D Center and a robust infrastructure, has always relied on nature to make good whatever mankind has lost in modernization. Gufic's vision is to grow into a global Bioscience major with its inherent value

systems that adheres to honesty in every action. Every step is taken towards enhancing the quality of human life back to the green future

Bio tech
Gufic started its plant biotechnology operation three years ago to produce and supply the high yielding and elite planting material of medicinal and other herbal plants using tissue culture techniques. The first biotechnology product was bixa, a source of natural food colour, for which the company has buy back arrangement with the farmers. Facility This company has a well developed tissue culture facility for production of 5 million plants per annum. The production unit is made by state of the art technology with six growth rooms, which can house 160000 culture bottles at a time. In the inoculation area, 30 persons can work in one shift. The air-conditioning and air handling system incorporates 5 micron and 0.5 micron filters and are designed for class 10,000 and class 100,000 as per us federal standards 209b. The work stations are however class 100.

Green house
The company has two green houses of 800 square meters with evaporative cooling, misting and shading equipment for hardening of tissue culture plants. In addition the company has shade houses for hardening of plants at 4 loacations. Product This facility is being used for production of banana, potato, sugarcane, date palm, jatropha for indian market. The company has developed in-house, on line real time computer software for forward planning of production schedule to meet market demands as well as monitoring daily production schedule and generating mis reports. The company has highly motivated ph.d. and m.sc. personnel who man our production facility. They are supported by highly enthusiastic and hardworking staff who are ever willing to give better productivity both in qualitative and quantitative terms. Bixa One of the major crops in which Gufic has interest is bixa, a source of natural food colour. The company proposes to have a buy-back for 500 acres of bixa plantation for which the tissue cultured plants are supplied to farmers under a buy-back agreement. Bixa tips Soil: Porous soils with good water leaching capacity are the best

Water logging soils like paddy fields are not recommended In slight alkaline soil, bixa can be planted with high amount of organic compost and FYM

Seeds
With the expertise created in the field of agriculture, over the years, along with the right type of research, Gufic has entered into hybrid vegetable seeds. Gufic seeds deals in all major vegetable seeds namely, tomato, chilli, cabbage, cauliflower, capsicum, coriander, bhendi, bottle gourd, bitter gourd, ridge gourd, brinjal, cucumber and watermelon. It is bringing out varieties/hybrids as per the local demands and preferences for particular characteristics in a crop. Towards this goal, Gufic seeds has already made arrangements with world class breeders and companies to get excellent seed material for development and promotions. Company commands the association of skilled, accomplished and seasoned professionals in research, production and marketing and we shall be striving to bring to you the best of hybrids and varieties to suit specific requirements on continues basis.

MOLECULE TABLETS Cefixime 100mg Cefixime 200mg Gatifloxacin 400mg. Levofloxacin 500mg. Norfloxacin 400mg. Ciprofloxacin 250mg Ciprofloxacin 500mg Nimuslide 100mg. Nimuslide 100mg

PACKING

NAME

INDICATION

10's 10's 10's 5's 10's 10 10 10's

EXIM 100 EXIM 200 GUFIGAT GUFILOX 500 GYROCIDE-400 ZIPCIN 250 ZIPCIN 500 MOLSLIDE

ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIINFLAMATORY

+ Paracetamol 500mg. Diclo. 50mg + Para 500mg + Chlorzoxazone 250mg. Aclofenac + Paracetamol Aclofenac + Paracetamol + Serratiopeptidase Diclofenac 50mg + Serratiopeptidase 10mg. Cetrizine 10mg. Levocitrazine 5mg.

10's 10's 10's

MOLSLIDE-P MOL PLUS MOLACE

ANTIINFLAMATORY ANTIINFLAMATORY ANTIINFLAMATORY

10's

MOLACE S

ANTIINFLAMATORY

10's 10's 10's

GUFISERA D GITZEN GITZEN L

ANTIINFLAMATORY ANTIALLERGIC ANTIALLERGIC

Levocitrazine 5mg + Amroxyl 60mg. Levocitrazine 5mg + Amroxyl 60mg + Para 500mg + Phenyl 2.5mg. Pentaprazole 40mg. Pentaprazole 40mg. + Domperidone 10mg. Ranitidine 150mg. Ranitidine 150mg. + Domperidon 10mg. Albendazole 400mg. Paracetamol 500mg. Paracetamol + Diclofenac Cefadroxil 125mg. Cefadroxil 250mg. Cefadroxil 500mg. Ciprofloxacin Hydrochloride 250mg. Ciprofloxacin Hydrochloride 500mg. Ciprofloxacin 500mg +Tinidazole 600mg. Co-trimoxazole DS Co-trimoxazole SS Serratiopeptidase 10mg. Mebendazole 100mg. Clotrimazole 100mg. Clotrimazole 200mg. 10's 1's 10's 10's 10's 10's 10's RIDCER D GUFIBEND MOL MOL-D GUFIDROX 125 GUFIDROX 250 GUFIDROX 500 ANTIULCERANT WORMICIDAL 10's 10's GEPAN D RIDCER 150 ANTIULCERANT ANTIULCERANT 10's GITZEN LA ANTIALLERGIC

10's 10's

GITZEN PLUS GEPAN

ANTIALLERGIC ANTIULCERANT

10's

ZIPCIN 250

10's

ZIPCIN 500

10's 10's 10's 10's 10X6 6's 3's

ZIPCIN TZ COTROX DS COTROX SS GUFISERA EBEN CANDO V 100 CANDO V 200

ANTI FUNGAL ANTI FUNGAL

capsules
Omperazole 20mg. 10's OPEL ANTIULCERENT

Omprozole 20mg + Domperidone 10mg. Ashwagadha 100mg + Kaunchbeej 100mg + Shatavari 100mg + Arjuna 100mg + Kali Musli 40mg + Kshir Vidari 25mg + Varahikand 22mg + Kokilaksha 12mg + Jatipatri 9mg + Akalkara 8mg + Shilajit 50mg + Yashad Bhasma 25mg Enzyme Cap. Cephalexin 250mg. Cephalexin 500mg. 10's 10's 10's 10's ONERGY GUFIZYME SUXIL 250 SUXIL 500 VIGOUR ANTIBIOTIC ANTIBIOTIC 10's OPEL-D ANTIULCERENT

Syrups Diphenhy 14.08

+ Amm Cit 0.138 + Sod. Cit 57.03 + Menthol 1.14mg + Alcohol 5% v/v

100ml

GUFIDRYL

COUGH SRYUP

Terbutaline Sulphate + Bromhexine Hydrochloride + Guaiphenesin Syrup 100ml. BROMAX COUGH SRYUP C. P. Mateate + Ammonium Chloride + Sodium Citrate Syrup 100ml. GEDEX COUGH SRYUP Acetaminophen 125mg + Pseudoephedrine 15mg + Dextromethor 60ML ROLLON COUGH &COLD Chlorpheniramine Maleate + Phenyl Propanolaminc HCL 12.5mg (with carton) 60ml. G COLD COUGH &COLD CPM + PPH + Paracetamol 125mg (with carton) 60ml. G COLD PLUS COUGH &COLD Levocetirizine Dihydrochloride 2.5mg. 30ml. GITZEN L ANTI ALLERGY Levocetirizine Dihydrochloride 2.5mg. + Ambroxol HCI 15mg. 30ml. GITZEN LA ANTI ALLERGY Cefixime Syrup 15gm/30ml. 30ml. EXIM ANTIBITOIC Cephalexin Dry Syrup 125mg/5ml 30ML SUXIL ANTIBITOIC Paracetamol Syrup 60ML. MOL ANTIPYRATIC Nimesulide + Paracetamol 60ml. MOLSLIDE P ANTIPYRATIC Ofloxacin 30ml. NIDIL

ANTIBACTERIAL Ofloxacin + Tinidazole 30ml. NIDIL TZ ANTIBACTERIAL Iron Syrup 200ml. GUFIRON IRON B Complex Syrup 200ml. GUFIBION BCOMPLEX Albendazole 200mg/5ml. 10ml GUFIBEND WORMICIDAL Antacid Syrup 170ml. GUFIGEL MPS ANTIACID Enzyme Syrup 200ML GUFIZYME ENZYME Cefadroxil Dry Syrup 125mg/5ml 30ml GUFIDROX Mebendazole Dry Syrup 125mg/5ml 30ml EBEN OINTMENTS / CREAMS & GELS Clotrimazole cream & Beclomethasone Diprpionate 15gm CANDO - B ANTI FUNGAL Clotrimazole Cream 15gm CANDO ANTI FUNGAL Pioviodine Ointment 15gm. GUFIDINE Silver Sulphadiazine USP 1%w/w Antiseptic Cream 15gm. SILVEREX Nimesulide Gel 30gm. MOLSLIDE GEL PAIN RELIVER Nimesulide 1.00%+Methyl Salicylate 10.3%+ Menthol 5.15% 30gm. MOLSLIDE PLUS GEL PAIN RELIVER Betamethasone 0.643 + Gentamicin + Tolnaftate + Idochlorohydroxy quinoline 5gm. GUFIDERM PAIN RELIVER Betamethasone Valerate 20GM BETANE PAIN RELIVER Betamethasone Valerate + Neomycin 20GM BETANE-N ANTI BACTRIAL Gama Benzene Hexacl 1% w/v Ointment 15gm GAB SCABICIDAL Pioviodine Ointment 15gm GUFIDINE ANTIMICROBIAL Silver Sulfadiazine & Chlorhexidine Gluconate Cream 15gm. GUFIREX SS BURNS Diclofenac Diethylammonium 1.16 gm (eqv. to Diclo Sod. 1% per 100gm) 30gm. GENEFEC GEL PAIN RELIVER Linseed Oil 3.0%, Diclofenac Diethylamine 1.16%, Methyl Salicylate 10.0% Menthol 5.0%, Benzyl Alcohol 1.0% 30gm. GENEFEC PLUS GEL PAIN RELIVER LOTIONS Gama Benzene Hexacl 1% w/v Lotion 100ml. GAB LOTION SCABICIDAL INJECTIONS Amikacin 100mg Vial GUFIMIKA 100MG Amikacin 500mg Vial GUFIMIKA 500MG Omeprazole 40mg. Vial OPEL ANTI ULCERNT Pentaprazole 40mg. Vial G PAN ANTI ULCERNT Ranitidine 2ml. Ampoule RIDCER ANTI ULCERNT Paracetamol 2ml. Ampoule MOL ANTI PYRETIC Metaclopramide 2ml. Ampoule TOMID Hydrocortisone Sodium Succinate Injection 100mg. Vial COTRISONE Diclofenac 3ml. Ampoule GEFENEC ANTIINFLAMATORY Ceftriaxone 1mg (With water for injection 10ml) Vial GUFITROX 1GM. ANTIBACTERIAL Ceftriaxone 250mg (With water for injection 3ml) Vial GUFITROX 250 Cefotaxim 1gm (With water for injection) Vial GUFITAX 1GM. Cefotaxim 250gm (With water for injection) Vial GUFITAX 250 OTHERS Clotrimazole Dusting Powder 75gm CANDO D.P. ANTI FUNGAL Oral Rehydration Salts ORS (Orange Flavour) 28.5gm GETRAL ORS ORS

http://www.guficbio.com/html/generic.html

http://www.moneycontrol.com/annual-report/guficbiosciences/rawmaterials/GB04#GB0

Capital Structure Period Instrument --- CAPITAL (Rs. cr) --- - P A I D U P - From To Authorised Issued Shares (nos) Face Value Capital 20102011Equity Share107.747735000017.7420092010Equity Share107.747735000017.7420082009Equity Share107.747735000017.7420072008Equity Share107.747735000017.7420062007Equity Share107.747735000017.7420052006Equity Share107.747735000017.7420042005Equity Share107.747735000017.7420012002Equity Share107.747735000107.7420002001Equity Share107.747735000107.7419992000Equity Share102.212210000102.2119941999Equity Share30.9900000100.919921994Equity Share10.9900000100.9